Ernst Rietschel

Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry

Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa

T2-high asthma phenotypes across lifespan

Guideline (S2k) on acute therapy and management of anaphylaxis: 2021 update

Leitlinie zu Akuttherapie und Management der Anaphylaxie - Update 2021

Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: A registry‐based case series

Management von Anaphylaxie-gefährdeten Patienten während der Covid-19-Pandemie

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for <i>F508del-CFTR</i>

Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial

Meta-analysis identifies seven susceptibility loci involved in the atopic march

Polymorphisms related to ORMDL3 are associated with asthma susceptibility, alterations in transcriptional regulation of ORMDL3, and changes in TH2 cytokine levels

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

Guideline for acute therapy and management of anaphylaxis

Changing the Mindset in Life Sciences Toward Translation: A Consensus

Leitlinie zu Akuttherapie und Management der Anaphylaxie

Inhalation Treatment with Glutathione in Patients with Cystic Fibrosis. A Randomized Clinical Trial

Different <i><scp>FCER</scp>1<scp>A</scp></i> polymorphisms influence <scp>I</scp>g<scp>E</scp> levels in asthmatics and non‐asthmatics